Add To My Watchlist

Green Zone Power Rating: 41 Neutral

Neutral stocks are expected to perform in line with the market over the next 12 months.
41
Price Based
Momentum
25
Size
66
Volatility
15
Fundamental Based
Value
52
Quality
42
Growth
81
Positive Factors (Top 20%)
Growth: High-growth stocks tend to outperform low-growth stocks.
Negative Factors (Bottom 20%)
Volatility: Stocks of the highest volatility typically underperform and pose unduly higher risk.
Collapse Detail

Latest Insights on DVAX

biopharma stock DVAX “Strong Bullish” Biopharma Stock Rips 130% Higher — and It’s Not Done
by Matthew Clark August 16, 2022 Investing
DVAX is a biopharma stock with promise as the company develops its signature hepatitis B vaccine. Here's why it's a buy today.